For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| LY900014 Test A | Test formulation A: Single dose of LY900014 formulation administered subcutaneously (SC) in one of five periods | 0 | None | 0 | 24 | 0 | 24 | View |
| LY900014 Test B | Test formulation B: Single dose of LY900014 formulation administered subcutaneously (SC) in one of five periods | 0 | None | 0 | 24 | 2 | 24 | View |
| LY900014 Test C | Test formulation C: Single dose of LY900014 formulation administered subcutaneously (SC) in one of five periods | 0 | None | 0 | 23 | 1 | 23 | View |
| LY900014 Test D | Test formulation D: Single dose of LY900014 formulation administered subcutaneously (SC) in one of five periods | 0 | None | 0 | 24 | 3 | 24 | View |
| Reference (Insulin Lispro, Humalog) | Reference formulation: Single dose of lispro administered SC in one of five periods | 0 | None | 0 | 24 | 1 | 24 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Catheter site related reaction | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA 18.1 | View |